William Hait - 14 Feb 2022 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
Officer
Signature
Raavi Deol, as attorney-in-fact for William Hait
Issuer symbol
JNJ
Transactions as of
14 Feb 2022
Net transactions value
+$4,901,552
Form type
4
Filing time
18 Feb 2022, 18:15:10 UTC
Previous filing
18 Feb 2022
Next filing
25 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +8,128 +11% $0.000000 84,394 15 Feb 2022 Direct F1
transaction JNJ Common Stock Tax liability $689,771 -4,158 -4.9% $165.89 80,236 15 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Employee Stock Options (Right to Buy) Award $5,591,322 +33,705 $165.89 33,705 14 Feb 2022 Common Stock 33,705 Direct F3
transaction JNJ Restricted Share Units Award $0 +3,413 $0.000000 3,413 14 Feb 2022 Common Stock 3,413 Direct F4
transaction JNJ Performance Share Units Options Exercise $0 -8,128 -91% $0.000000 775 15 Feb 2022 Common Stock 8,128 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting.
F2 Shares withheld for payment of taxes upon vesting of Performance Share Units.
F3 Awarded under Issuer's Long-Term Incentive Plan.
F4 Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant.
F5 Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited.

Remarks:

Title: Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer